Daraxonrasib, a new targeted therapy for pancreatic cancer supported by research from Columbia University, has received Food and Drug Administration (FDA) approval this week after demonstrating a near doubling of overall survival in patients with previously treated metastatic pancreatic cancer.
This approval follows results presented at the 2026 American Society of Clinical Oncology Annual Meeting, which showed the drug significantly extended the lives of patients with the most common form of the disease. This represents one of the most significant breakthroughs in pancreatic cancer in decades, a disease where treatment advances have historically been measured in weeks rather than months.
Gulam Manji, a pancreatic cancer specialist and Columbia’s principal investigator for the daraxonrasib trials, expressed enthusiasm for the development. “To see a therapy nearly double overall survival in a phase 3 study is remarkable,” Manji said. “These results validate years of research and bring us closer to a future where more patients with pancreatic cancer have effective treatment options.”